FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to treating arthropathies, such as arthrosis and inflammatory loss of cartilage, tendon disorders and/or degenerative spine diseases. What is presented is a pharmaceutical composition for the above application, containing a corticosteroid and a cytokine antagonist - a natural or recombinant protein of interleukin IL-1Ra antagonist, particularly orthokine or anakinra, and optionally a growth factor; the composition is injectable into an injured nerve root, or into an injured intervertebral disk, or into their local context, or for intraarticular injection. There are presented: a kit comprising the pharmaceutical composition with the above cytokine antagonist and optionally the growth factor, and the pharmaceutical composition with the corticosteroid; using the above cytokine antagonist and optionally the growth factor for preparing the pharmaceutical composition to be used in combination therapy together with the corticosteroid for the above application; using the corticosteroid for preparing the pharmaceutical composition to be used in combination therapy with the above cytokine antagonist and optionally the growth factor for treating the above arthropathies, tendon disorders and/or degenerative spine diseases.
EFFECT: clinical success of treatment manifested by apparent joint detumescence, pain reduction by 60-100%, functional improvement of the joint, with the effect persisting 8 months later and more after the treatment.
39 cl, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
COMBINATION DRUG CONTAINING CORTICOSTEROID AND EXOSOMES | 2010 |
|
RU2557897C2 |
AGONISTS AND ANTAGONISTS OF HYBRID IL-1 RECEPTOR OF I TYPE | 2011 |
|
RU2754957C2 |
METHODS OF TREATMENT OR PREVENTION OF ASTHMA THROUGH ADMINISTRATION OF IL-4R ANTAGONIST | 2013 |
|
RU2801531C2 |
THERAPEUTIC PRODUCT CONTAINING IL-33 ANTAGONIST FOR THE TREATMENT OF ENDOMETRIOSIS | 2018 |
|
RU2791705C2 |
NOVEL PROTEIN CONJUGATE AND USE THEREOF FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES | 2021 |
|
RU2822001C1 |
IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
INTERLEUKIN-18 OPTIONS AND METHODS FOR THEIR USE | 2018 |
|
RU2797536C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
ANTIBODIES, THEIR APPLICATION AND METHODS OF APPLICATION | 2016 |
|
RU2725221C2 |
ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
Authors
Dates
2014-08-20—Published
2010-12-10—Filed